Toxic epidermal necrolysis (TEN) is a severe drug-induced bullous eruption that has significant mortality and morbidity.1 Induction of Fas ligand, a cytokine that induces apoptosis, may mediate cell death in TEN in part because the soluble Fas ligand (sFasL) level is elevated in the blood of patients with TEN.2 Pooled human immunoglobulin blocks the action of Fas and may be beneficial in TEN.2 The kinetics and specificity of sFasL induction in TEN and other bullous dermatoses are unknown. We present preliminary results of serial sFasL measurement in a patient with TEN and 10 patients with 5 types of chronic bullous diseases.
Clinical and histologic findings of a patient with toxic epidermal necrolysis. A, Erosion on the lips and hard palate and scattered bullae with erythematous macules were noted on the first day of the skin eruption. B and C, The erythematous macules on the trunk and soles progressed to tense bullae by day 2. By day 7 oral lesions had healed (D) and most of the bullae were covered by hemorrhagic crust and had begun reepithelialization (E). F, Skin with subepidermal split (arrow) and an overlying area of confluent epidermal necrosis (arrowhead) (hematoxylin-eosin, original magnification ×100). The dermis shows only a sparse lymphohistiocytic infiltrate.
Serologic studies of soluble Fas ligand (sFasL). A, Kinetics of sFasL in toxic epidermal necrolysis. Concentration of sFasL is shown on the left axis and the extent of total body surface area (TBSA) involved by toxic epidermal necrolysis is estimated on the right axis. sFasL was measured in triplicate, and the mean values are shown. The SD ranges from 15.2% to 20% of the mean value. Arrowheads signify the times when immunoglobulin (IVIG) was infused. The upper limit of normal level of sFasL (0.1 ng/mL) is shown by the dashed line. B, Specificity of sFasL in autoimmune bullous diseases. Shown are serum levels of sFasL in a normal donor; patients with bullous pemphigoid (BP); subepidermal, lamina lucida blistering disease (Chan disease)4; cicatricial pemphigoid (CP); epidermolysis bullosa acquisita (EBA); linear IgA bullous dermatosis (LABD); and pemphigus vulgaris (PV). Dashed line denotes upper limit of normal level of sFasL.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Dermatology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 4
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.